Topic summary

What a regulator's shortage notice actually authorises

Sourcing › Regulatory personal import research use only EMA FDA compounding Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 13, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

bench_entryTL3Regular22 Jun 2026#1

What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked.

A logistics question, since the answers here are usually better than anywhere else I have looked.

Parcel despatched 14 days ago, tracking last updated 5 days ago at a customs facility, no further movement. Cold pack included at despatch.

Two questions. First, at what point is this genuinely a problem rather than an ordinary delay? Second, if it does arrive, what is the actual decision process for assessing it, as opposed to the two extremes people usually offer?

20 likes 1mo

s.chowdhuryTL3Regular27 Jun 2026#2

Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date attached.

23 likes 1mo

sourced_claimsTL3Regular10 Jul 2026#6

On post #2 — agreed on the reasoning, with one qualification.

Preclinical versus clinical: compounds with strong preclinical data can fail in clinical trials. Compounds with no human data are being used on theoretical grounds. The regulatory position reflects this asymmetry.

31 likes 18d

y.eriksenTL2 Moderator Solution18 Jul 2026#9

post #8 is right about the mechanism and I think understates the practical bit.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

7 likes 10d

lc_gradientTL3Analytical chemist22 Jul 2026#11

Why this category is maintained as documentation, not as recommendations: the goal is factual accuracy and sourcing, not endorsement of any specific regulatory position.

30 likes 5d

Read the full topic (13 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product quality.…		2	62k	15mo
Research-use-only labelling: what it means and what it does not — the long version Sourcing › Regulatory EMA research use only compounding Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. I would like to talk about…	+150	158	55k	14mo
Prescription requirements and telehealth models Sourcing › Regulatory FDA compounding research use only MHRA Prescription requirements and telehealth models Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are usually better than anywhere…	+91	97	5.4k	7mo
Coming back to: Research-use-only labelling: what it means and what it does not Sourcing › Regulatory MHRA personal import research use only Solved Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…	+45	50	39k	20mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…	+76	82	52k	11mo

Related topics — sharing the tags personal import, research use only, EMA

Topic	Participants	Replies	Views	Activity
Second pass at: What to keep a record of at the point of payment Sourcing › Payments payments research use only documentation quality Second pass at: What to keep a record of at the point of payment — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually better than…	+14	18	1.9k	4mo
Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA MHRA research use only EMA Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…	+72	78	23k	3mo
Research-use-only status: what it means legally and practically — does this still hold? Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Pinned Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Session topic: SELECT ( N Engl J Med , 2023). Please read…		2	309	9mo
Naming conventions for research peptides and the confusion they cause Compounds › Other compounds custom synthesis mislabelling research use only needs a source Posting this under the heading it deserves: Naming conventions for research peptides and the confusion they cause Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with STEP 1 ( N…	+21	25	4.9k	22d
Follow-up: UK access routes, dated and sourced Regional › UK & Ireland personal import cost per milligram MHRA Solved On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of May 2026, in…	+10	14	27k	2d